uploads///collaboration revenue

Regeneron Pharmaceuticals’ Collaboration Revenue in 1Q16


May. 16 2016, Updated 6:07 p.m. ET

Collaboration revenue 

Regeneron Pharmaceuticals’ (REGN) total collaboration revenue in 1Q16 came in at $399 million. Higher collaboration revenue was due to the following factors:

  • higher R&D (research and development) expense reimbursement under antibody collaboration with Sanofi (SNY)
  • increased non-US net profit from Eylea
  • R&D expense reimbursements
  • amortization of up-front payments “received in connection with the immuno-oncology collaboration with Sanofi”

Article continues below advertisement

Sanofi and Bayer collaboration agreements

In 1Q16, collaboration revenue from Sanofi (SNY) increased to $219.7 million from $173.4 in 1Q15 while the collaboration revenue from Bayer jumped to $179.6 million from the previous year’s comparable revenue of $123.8 million. Sanofi collaboration revenues include reimbursements related to antibody and immuno-oncology programs. For details on the terms of the collaboration agreement with Sanofi, read Regeneron Enters into a Collaboration with Sanofi-Aventis.

Bayer collaboration revenues include net profit from Eylea’s non-US sales along with the joint development and commercialization of Platelet-Derived Growth Factor Receptor Beta (PDGFR-beta) and angiopoietin-2 (Ang2) outside the US. The details of the terms of the collaboration agreement with Bayer can be found at Regeneron Enters into a Collaboration with Bayer HealthCare.

To control excessive company-specific risks but at the same time get exposure to REGN, you can invest in the iShares Russell 1000 Growth ETF (IWF). The fund invests 4.2% of its holdings in the biotechnology sector. Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), and Amgen (AMGN) account for 1.1% each of the fund’s total assets. REGN accounts for 0.28% of IWF’s total holdings.

In the next article in this series, we’ll further analyze the key drug Eylea’s performance in 1Q16.


More From Market Realist

  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.